Many sponsors struggle with unclear regulatory pathways, uncertainty about site readiness, and lingering misconceptions about data quality coming out of the region. Some of that hesitation is fair. Some of it is outdated.
A 2024 industry analysis found that approved Russian clinical studies dropped from 908 in 2021 to 740 in 2022, an 18.5% decline, while Western sponsor participation fell from 61% to 32% of filings. That's a real shift. But it's not the whole story across the CIS/EAEU bloc.
This article walks through the regulatory frameworks, country-by-country realities, site readiness benchmarks, and risk mitigation tactics sponsors need before committing to the region.
Key Takeaways
- CIS countries offer large treatment-naive patient pools and competitive per-patient costs, but timelines vary sharply by country.
- EAEU harmonization is pushing member states toward CTD-format dossiers, though language and sequencing rules still differ nationally.
- Site readiness (GCP status, PI experience, data infrastructure) is often underestimated and should be independently verified, not assumed.
- Diversifying across Kazakhstan, Armenia, and Georgia hedges against disruption concentrated in any single market.
The Regulatory Landscape in CIS Countries
CIS and EAEU regulatory frameworks are built on ICH-GCP principles, but each country layers on its own national requirements. Dual-language documentation, specific ethics committee sequencing, and local submission quirks are standard requirements.
The EAEU harmonization initiative, formalized under EEC Council Decision No. 78, requires registration dossiers to follow the CTD format across five core modules. Administrative information and CTD summaries (Modules 1-2) generally need local-language versions, while clinical Module 5 can often stay in English. Legacy products registered before the end of 2020 had until the end of 2025 to transition to this format.
What Sponsors Must Prepare
Mandatory documentation for Clinical Trial Authorization typically includes:
- Investigational Medicinal Product Dossier (IMPD) or equivalent quality/manufacturing package
- GMP certificates and certificate of analysis
- Protocol, Investigator's Brochure, and informed consent materials
- Power of Attorney where the sponsor has no local legal entity
Several jurisdictions require a local legal representative to execute site contracts and manage regulatory correspondence. Georgia's 2024 framework, for instance, explicitly requires a local legal entity, including a CRO, to hold and submit the CTA.
The Sponsor Composition Shift
Post-2022, trial sponsorship in the region shifted sharply:
- Russian sponsors' share rose from 45.7% to 71%
- Non-Russian EAEU sponsors climbed from 1% to 32% by Q4 2022
- Generic and bioequivalence studies made up 69% of 2022 approvals
- Phase III share dropped to 25%
This reflects a pivot toward regional and generic-focused development rather than innovative Western-sponsored trials.
Site Readiness: What Sponsors Need to Verify
Core site readiness comes down to three pillars: GCP certification status, PI experience thresholds (years in research, therapeutic specialization), and infrastructure for data capture. None of these should be taken on faith; they need independent verification before site selection.
Verifying Data Quality and Compliance
The perception that CIS data is lower quality does not match the evidence. A large historical study covering 4,721 sites and 1.39 million data queries found no statistically significant regional differences in query or database-change rates compared to North America or Western Europe.
FDA and EMA inspections at sites in this broader region have historically met acceptable compliance benchmarks. ICH-GCP compliance, as EMA describes it, exists specifically to support mutual acceptance of trial data across regulatory regions. That said, sponsors shouldn't assume automatic acceptance — data integrity and inspection-readiness still require case-by-case review.
Assessing Operational Capabilities
Before greenlighting a site, verify:
- GCP certification status and recent inspection history
- PI experience: years in research and therapeutic specialization
- Patient recruitment infrastructure and hospital/clinical center density
- EDC/eCRF system compatibility with your data management platform
- Multilingual documentation capacity for consent forms and case report forms
- Established communication channels with local regulators
After operational fit is confirmed, pre-submission consultations with regulatory bodies consistently shorten review timelines. Skipping that step remains one of the most common, avoidable causes of dossier delays.
Country-Specific Considerations Across the CIS Region
Approval timelines and requirements vary widely across the bloc. Here's a snapshot:
| Country | Approval Timeline | Key Requirement |
|---|---|---|
| Kazakhstan | ~20 weeks; actual review often 3-7 months | Dual Kazakh/Russian documentation; POA must be apostilled |
| Belarus | No verified numeric benchmark; MoH decision follows technical review | 2020 MoH clinical-trial resolution governs process |
| Armenia | 40-70 MoH review days, plus 3-5 weeks dossier prep | Armenian-language trial program required |
| Georgia | ~30 calendar days (RA) if no questions; ~2 months average | Local legal entity or CRO must hold the CTA |
Georgia stands out as an EU-associated, regionally adjacent option outside the CIS. It offers full ICH-GCP compliance and among the fastest timelines in the region, making it attractive for sponsors diversifying away from sanctioned markets.
Budget individually for each country. Currency handling, IMP import/customs procedures, and insurance requirements don't transfer cleanly between jurisdictions:
- Georgia: Regulatory approval doubles as import authorization (no separate license); local insurance coverage is mandatory
- Kazakhstan: IMP export/import license is bundled into trial approval, but health insurance documentation is separate
These aren't interchangeable processes, and treating them as such is a common budgeting mistake.
Mitigating Risk: Building a Resilient Multi-Country Strategy
A single-country CIS strategy is a fragile one. Political and regulatory conditions in this region can shift quickly, and sponsors who've built contingency plans around backup countries within the EAEU/CIS bloc keep timelines intact when disruption hits.
Practical steps for building resilience:
- Map backup sites early: identify comparable sites in at least one alternative country before submission, not after disruption hits
- Use on-the-ground regulatory intelligence: bureaucratic variability and contract nuances are hard to manage remotely
- Budget local legal representation from day one: treat it as a core setup cost, not an afterthought
- Diversify across Kazakhstan, Armenia, and Georgia: spread exposure across multiple regulatory environments
This is where an experienced CRO partner matters. DRK Research Solutions works across regulated and emerging markets, pairing global regulatory strategy with local execution support.
Its clinical trial planning services include regulatory strategy development, eCTD dossier preparation for Modules 2–5, and GxP compliance support. That mix helps sponsors interpret EAEU harmonization requirements, track shifting national rules, and judge whether a site or country truly fits their risk tolerance.
Frequently Asked Questions
Is data from clinical trials conducted in CIS countries accepted by the FDA and EMA?
ICH-GCP compliant sites in the region regularly produce data that meets international regulatory standards, and inspection outcomes have historically been comparable to other regions. Acceptance still depends on sponsor-specific data integrity and inspection readiness.
How long does regulatory approval typically take in CIS countries?
Timelines range from about 30 days in Georgia to 3-7 months in Kazakhstan, depending on submission sequence and country. Belarus and Kyrgyzstan lack a consistently published benchmark, so build in buffer time.
What documents are required to get Clinical Trial Authorization in CIS/EAEU countries?
Core requirements typically include an IMPD or quality dossier, GMP certificate, protocol, informed consent forms, and a Power of Attorney if you lack a local legal entity. Exact requirements vary by country.
Are there hidden costs when running trials in CIS countries?
Yes. Import/customs procedures for investigational products, currency fluctuations, and local insurance requirements can add unbudgeted expense. Transparent, country-specific CRO budgeting helps avoid surprises.
Which CIS countries are considered the most viable alternatives amid ongoing disruptions?
Kazakhstan, Armenia, and Georgia currently offer the clearest regulatory pathways and most documented operational evidence within the region. Kyrgyzstan remains an emerging option with less published data.
Do sponsors need a local legal entity to run trials in CIS countries?
In several jurisdictions, yes. Georgia requires a local legal entity or CRO to hold the CTA, and Kazakhstan requires an apostilled Power of Attorney when the applicant is not the sponsor. A partner CRO can often fill this role.
